Last updated on March 2019

Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic Well-differentiated Non-functional Neuroendocrine Tumors of Pancreatic Gastrointestinal (GI) or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)

Brief description of study

This is a study to investigate the efficacy and safety of PDR001 in patients with advanced or metastatic, well-differentiated, non-functional neuroendocrine tumors of pancreatic, gastrointestinal (GI), or thoracic origin or poorly-differentiated gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC) that have progressed on prior treatment.

Clinical Study Identifier: NCT02955069

Contact Investigators or Research Sites near you

Start Over

Novartis Investigative Site

Erlangen, Germany
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.